ABROCITINIB TREATMENT IN ADOLESCENTS AND ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: EARLY PRURITUS RESPONSES FROM PHASE 3 TRIALS JADE MONO-1 AND JADE MONO-2

被引：0

作者：

Stander, Sonja ^{[1
]}

Yosipovitch, Gil ^{[2
]}

Silverberg, Jonathan I. ^{[3
]}

Simpson, Eric L. ^{[4
]}

Sinclair, Rodney ^{[5
]}

Su, John C. ^{[6
,7
,8
]}

Kerkmann, Urs ^{[9
]}

Gallardo, William Romero ^{[10
]}

Valdez, Hernan ^{[11
]}

Rojo, Ricardo ^{[12
]}

Biswas, Pinaki ^{[13
]}

Farooqui, Saleem A. ^{[14
]}

机构：

[1] Munster Univ Hosp, Dept Dermatol, Ctr Chron Pruritus, Munster, Germany

[2] Univ Miami, Miller Sch Med, Miami Itch Ctr, Miami, FL USA

[3] George Washington Univ, Sch Med & Hlth Sci, Dept Dermatol, Washington, DC 20052 USA

[4] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA

[5] Sinclair Dermatol, East Melbourne, Vic, Australia

[6] Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Dept Populat Allergy, Parkville, Vic, Australia

[7] Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Dept Dermatol, Parkville, Vic, Australia

[8] Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Dept Paediat, Parkville, Vic, Australia

[9] Pfizer Pharma GmbH, Global Med Affairs Inflammat & Immunol, Berlin, Germany

[10] Pfizer Ltd, Global Med Affairs Inflammat & Immunol, Surrey, England

[11] Pfizer Inc, Global Prod Dev Inflammat & Immunol, New York, NY USA

[12] Pfizer Inc, Global Prod Dev Inflammat & Immunol, Groton, CT USA

[13] Pfizer Inc, Biostat, New York, NY USA

[14] Pfizer Ltd, Clin Dev & Operat, Surrey, England

来源：

ACTA DERMATO-VENEREOLOGICA | 2021年 / 101卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

PT13

引用

页码：56 / 56

页数：1

共 50 条

[21] Long-term efficacy of abrocitinib in adolescents and adults with moderate-to-severe atopic dermatitis: a post hoc analysis of JADE EXTEND
Paller, Amy S.
Cork, Michael J.
Flohr, Carsten
Bangert, Christine
Weidinger, Stephan
Nesnas, John
Farooqui, Saleem A.
Biswas, Pinaki
Watkins, Melissa
Koppensteiner, Herwig
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
[22] Efficacy and Safety of Abrocitinib in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (AD): Results From the Phase 3 JADE TEEN study
Eichenfield, Lawrence
Flohr, Carsten
Sidbury, Robert
Szalai, Zsuzsanna
Galus, Ryszard
Yao, Zhirong
Takahashi, Hidetoshi
Barbarot, S. Ebastien
Feeney, Claire
Zhang, Fan
DiBonaventura, Marco
Rojo, Ricardo
Valdez, Hernan
Chan, Gary
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB146 - AB146
[23] Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study
Alexis, Andrew
de Bruin-Weller, Marjolein
Weidinger, Stephan
Soong, Weily
Barbarot, Sebastien
Ionita, Ileana
Zhang, Fan
Valdez, Hernan
Clibborn, Claire
Yin, Natalie
DERMATOLOGY AND THERAPY, 2022, 12 (03) : 771 - 785
[24] Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study
Andrew Alexis
Marjolein de Bruin-Weller
Stephan Weidinger
Weily Soong
Sebastien Barbarot
Ileana Ionita
Fan Zhang
Hernan Valdez
Claire Clibborn
Natalie Yin
Dermatology and Therapy, 2022, 12 : 771 - 785
[25] Relationship between pruritus, sleep, and quality of life (QOL) in atopic dermatitis (AD): post hoc analysis of JADE MONO-2
Sinclair, R.
Eisman, S.
Murrell, D. F.
Su, J. C.
Feeney, C.
DiBonaventura, M.
Biswas, P.
Cameron, M.
Surian, C.
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2021, 62 : 124 - 125
[26] Long-term management of moderate-to-severe atopic dermatitis with abrocitinib: a phase III extension study (JADE EXTEND)
Reich, K.
Silverberg, J. I.
Papp, K.
Deleuran, M.
Katoh, N.
Strober, B.
Beck, L. A.
de Bruin-Weller, M.
Werfel, T.
Zhang, F.
Biswas, P.
DiBonaventura, M.
Chan, G. L.
Farooqui, S. A.
Kerkmann, U.
Clibborn, C.
BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E141 - E142
[27] Abrocitinib in the Treatment of Moderate-to-Severe Atopic Dermatitis Refractory to Dupilumab Treatment: An Analysis of JADE-EXTEND, a Phase 3 Long Term Extension Study
Shi, Vivian Y.
Bhutani, Tina
Deleuran, Mette
Fonacier, Luz
Shumack, Stephen
Zhang, Fan
Cameron, Michael C.
Chan, Gary
Valdez, Hernan
Yin, Natalie
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 77 - 78
[28] Bone safety data in adolescents with moderate-to-severe atopic dermatitis treated with abrocitinib: interim results from the JADE EXTEND MRI substudy
Zdybski, J.
Wollenberg, A.
Flohr, C.
Brunner, P. M.
Hoegler, W.
Egeberg, A.
Irvine, A. D.
Fan, H.
Biswas, P.
Radi, Z.
Farooqui, S. A.
Koppensteiner, H.
Sherlock, S. P.
Chan, G.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (11) : S366 - S366
[29] Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis The JADE TEEN Randomized Clinical Trial
Eichenfield, Lawrence F.
Flohr, Carsten
Sidbury, Robert
Siegfried, Elaine
Szalai, Zsuzsanna
Galus, Ryszard
Yao, Zhirong
Takahashi, Hidetoshi
Barbarot, Sebastien
Feeney, Claire
Zhang, Fan
DiBonaventura, Marco
Rojo, Ricardo
Valdez, Hernan
Chan, Gary
JAMA DERMATOLOGY, 2021, 157 (10) : 1165 - 1173
[30] The impact of abrocitinib on vaccine-induced immune responses in adolescents with moderate-to-severe atopic dermatitis undergoing routine tetanus, diphtheria, and pertussis vaccination in phase 3 JADE TEEN
Cork, Michael
Eichenfield, Lawrence
Flohr, Carsten
Bangert, Christine
Barbarot, Sebastien
Rojo, Ricardo
Chan, Gary
Zhang, Fan
Feeney, Claire
Valdez, Hernan
ALLERGY AND ASTHMA PROCEEDINGS, 2024, 45 (01)

← 1 2 3 4 5 →